Behind Sanofi’s Established Product Performance in 3Q17
Established prescription products
Sanofi’s (SNY) general medicines and emerging markets businesses include established prescription products, generic products, and revenues from emerging markets. For 3Q17, revenues from established prescription products fell 6.5% YoY (year-over-year) at constant exchange rates to 2.26 billion euros.
Interested in FVD? Don't miss the next report.
Receive e-mail alerts for new research on FVD
The fall in revenues in 3Q17 was driven by lower sales of Plavix, Lovenox, Renagel, Aprovel, Allegra, Myslee, Targocid, and few other drugs, partially offset by a rise in Depakine sales.
Lovenox’s revenues rose 5.4% at constant exchange rates to 370 million euros in 3Q17, driven by lower sales in Europe and the rest of the world, partially offset by a rise in US sales and revenues from emerging markets. Sales from European markets fell 10.9% to 220 million euros in 3Q17 due to competition from other products.
Plavix revenues fell 4.7% at constant exchange rates to 358 million euros during 3Q17, driven by a 7.5% fall in European sales to 37 million euros and a 28.2% fall in sales from rest of the world, excluding emerging markets and European markets. Sales from emerging markets rose 5% to 254 million euros.
Renagel and Renvela
Renagel and Renvela reported a combined 35.1% fall in revenues at constant exchange rates to 153 million euros for 3Q17. This decline was due to lower sales in US markets, European markets, and rest of the world, partially offset by a rise in revenues from emerging markets.
Notably, the First Trust Value Line Dividend ETF (FVD) has 6.7% of its total investments in the healthcare Sector, with 0.5% in Sanofi ADR (SNY), 0.5% in GlaxoSmithKline ADR (GSK), 0.5% in Merck (MRK), and 0.5% in Novartis ADR (NVS).